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medicinal products
 
James W. Dear, Pajaree Lilitkarntakul & David J. Webb
 
Clinical Pharmacology Unit, Centre for Cardiovascular Science, University of Edinburgh, Queen’s Medical Research Institute, Edinburgh, UK
 
Orphan medicinal products (OMPs) are targeted at the diagnosis, prevention or
treatment of rare diseases and have a special status in European law. This status
brings incentives for pharmaceutical companies to invest in OMP development. The
goal of the legislation is to encourage the development of more treatments for life-
threatening rare disorders, but increased availability of OMPs raises important issues
surrounding the public funding of very expensive treatments by national health
services. In this article we review OMPs and the incentives for their development and
discuss the challenges presented by funding these treatments.
 
Introduction
 
Orphan medicinal products (OMPs) are those medicines
intended for the diagnosis, prevention or treatment of
rare disorders. The label ‘orphan’ arose largely because
such drugs yield little financial return on investment
because of the limited size of the rare disease drug
market and therefore pharmaceutical companies have
shown little interest in ‘adopting’ treatments for rare
diseases. Although individually rare, collectively these
diseases affect about 30 million Europeans and 25 mil-
lion North Americans [1]. Many of these diseases have
no effective treatments and therefore rare diseases pose
a substantial public health concern.
Over the last 23 years legislation has been created in
the USA (1983), Japan (1993), Australia (1998) and
Europe (2000) to provide incentives for the development
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of OMPs. In this review article we discuss the European
and American definitions of orphan disease, the incen-
tives available to encourage product development and
the challenges of funding the clinical use of OMPs.
 
Definitions
 
A rare disease or ‘orphan’ disease is defined as one that
affects a restricted number of people. Definitions use
prevalence of disease as the main criterion (Table 1). In
the USA, the Orphan Drug Act (1983) defines orphan
disease as a disease or condition which affects 
 
<
 
200 000
people in the USA or has a prevalence of 
 
<
 
7.5 per
10 000 Americans [2]. The definition for orphan disease
agreed by the European Committee for Orphan Medic-
inal Products (COMP) [3] is a life-threatening or very
serious disease affecting not more than five per 10 000
Europeans (the USA definition does not specify disease
severity) [4]. A diagnostic assay, preventative or thera-
peutic agent with a rationale for use in a specific orphan
disease can apply to have the status of an OMP. If proper
scientific justification of the intended use is submitted,
orphan designation may be obtained at any stage of
development (preclinical or clinical). However, designa-
tion as an OMP is not approval for the use of the drug
in the orphan condition. It does not indicate that the
product has the amount of data regarding efficacy, safety
and quality required for marketing authorization. Simi-
lar to the requirements for any other medicinal product,
these criteria can only be assessed once the application
for marketing authorization has been submitted. The
European designation process for orphan medicines is
determined by COMP and takes a maximum of 90 days
from submission of the application to receipt of an opin-
ion. The European Commission’s (EC’s) decision then
follows in a maximum of 30 days.
OMP status provides valuable benefits to the drug
producer but is defined by an ‘all or nothing’ arbitrary
cut-off in disease prevalence. Therefore, a product to
treat a disease with a prevalence of five per 10 000
Europeans can benefit from a number of incentives but
if the disease prevalence were six per 10 000 these
incentives would not be available. While the disease
may be rare in Europe, it may be common elsewhere;
for example, drugs to treat tropical diseases can benefit
from orphan status in Europe, which may be reasonable
given the differences in resources available in Europe
compared with countries affected by tropical disease. A
disease which is more common in one European mem-
ber state may also qualify for orphan status if the overall
prevalence across Europe is less than five per 10 000
(e.g. Balkan nephropathy). Disease redefinition in the
postgenomic era may create many new diseases that
meet the criteria for orphan status [5]. For example,
sepsis is a relatively common disease, accounting for a
 
Table 1
 
Definitions
 
Orphan disease
 
 – A disease which has not been ‘adopted’ by the pharmaceutical industry because the small market provides little financial 
incentive for the private sector to make and market new medications to treat or prevent it. The definition is based on disease prevalence and 
differs between Europe and the USA
 
European definition.
 
 Life-threatening or very serious disease affecting not more than five in 10 000 people in the European Community. This 
includes tropical diseases which are uncommon in Europe but common elsewhere
 
USA definition.
 
 The term ‘rare disease or condition’ means any disease or condition which (a) affects 
 
<
 
200 000 persons in the USA, or (b) 
affects 
 
>
 
200 000 persons in the USA and for which there is no reasonable expectation that the cost of developing and making available in the 
USA a drug for such disease or condition will be recovered from sales in the USA of such drug
 
Ultra-orphan disease
 
 – A very rare disease. There is no formal definition but the National Institute of Clinical Excellence uses the term for 
diseases affecting 
 
<
 
1000 people in England and Wales
 
Orphan medicinal product (OMP)
 
 – Products for the diagnosis, prevention or treatment of orphan diseases. For OMP designation in Europe 
there needs to be no satisfactory method of diagnosis, prevention or treatment of the orphan disease in the European Community. Alternatively, 
the medicinal product must confer a significant benefit compared with the existing diagnostic, preventative or therapeutic products available for 
the orphan disease
 
USA Orphan Drug Act (1983) and EU Orphan Drug Regulation (2000)
 
 — Legislation designed to encourage the development of OMPs. In 
both territories there is marketing exclusivity which prevents any competitor gaining market access unless superiority is demonstrated. In both 
territories the regulatory authorities offer assistance in the design of clinical trials; and they waive their normal licensing fees. In the USA (but 
not the EU) there is also tax relief and the possibility of access to ear-marked research grants.
 
ICER (incremental cost-effectiveness ratio)
 
 – The financial cost for each extra unit of health improvement gained by using the intervention
 
QALY (quality-adjusted life year)
 
 – A measure of the quantity and quality of life generated by a healthcare intervention. Provides a unit which 
can be used to compare different interventions
 J. W. Dear et al. 
 
266
 
62
 
:3
 
Br J Clin Pharmacol
 
similar number of deaths to myocardial infarction in the
USA [6]. Considerable efforts are underway to define
subgroups of septic patients by investigating host sus-
ceptibility factors (e.g. single nucleotide polymor-
phisms) [7], biomarkers of host response pathways [8]
and pathogen virulence factors [9]. These studies may
lead to subgroups of sepsis which will be sufficiently
rare to apply for the benefits of orphan status. Whether
such disease subgroups should be considered as orphans
remains unclear, but sponsors applying for orphan status
will have to produce convincing evidence that their
product is subgroup specific [10].
Orphan diseases are defined by their rarity. However,
if a disease has a prevalence of five per 10 000 then in
a country of 60 million (UK) there may be 30 000 cases
and across the EC there may be over 200 000 people
affected. These patient numbers should provide a large
enough pool from which to draw subjects for adequately
powered clinical trials, an issue we will return to later.
This size of OMP market may also allow a pharmaceu-
tical company to make a substantial return on invest-
ment while still benefiting from the incentives given to
orphan drug status. The terms ‘ultra-orphan’ disease and
‘ultra-orphan’ medicinal product (uOMP) have recently
been coined to describe very rare diseases and their
treatments, and draw a distinction with the ‘commoner’
orphan diseases. The definition used by National Insti-
tute of Clinical Excellence (NICE) is less than 1000
cases in England and Wales.
 
Incentives for the development of orphan 
medicinal products
 
The process for approval of a new drug is complex and
expensive, requiring an average of 10–15 years for com-
pletion. By definition, the OMP market is small and this
makes orphan diseases potentially unprofitable for phar-
maceutical and biotechnology companies. The USA
Orphan Drug Act and European legislation provide
incentives intended to stimulate research and develop-
ment on, and approval of, products with orphan status.
The European and US legislations are compared in
Table 2. Since 2000, 295 products have been granted
orphan status in Europe and 21 have progressed to mar-
ket approval (Table 3). For comparison, between 1995
and 2000 only 12 medicines for rare diseases came to
market in Europe. Although not an exact comparison,
because the USA Orphan Drug Act predates European
law, 473 products have been given orphan designation
in the USA since 2000 and, of these, 23 have market
approval. By contrast, in the 10 years before the USA
Orphan Drug Act, only 10 products were approved for
treatment of rare disease [10]. The diseases with the
most products designated orphan status in Europe are
cystic fibrosis and renal cell carcinoma, each having 10
OMPs (although none yet with European market
approval).
The incentives for OMP development are market
exclusivity, protocol assistance, fee reduction, tax cred-
its (in the USA) and specific grants for OMP trials.
 
Marketing exclusivity
 
This is the main factor encouraging pharmaceutical
companies to develop specific OMPs. The Regulation
(EC) no. 141/2000 of the European Parliament and of
the Council of 16 December 1999 grants OMPs market
exclusivity for 10 years after approval, whilst sponsors
are granted exclusivity for 7 years in the USA [2, 4].
During that authorized period, no similar competitive
 
Table 2
 
Comparison of European and US orphan medicinal product (OMP) development
 
Europe USA
 
Date of legislation creating incentives for OMP
development
2000 1983
To date, number of products given OMP status Total number 295 Total number 1494
59 per year since creation of legislation 68 per year since creation of legislation
To date, number of OMPs with market approval Total number 21 Total number 268
4 per year since creation of legislation 12 per year since creation of legislation
Incentives available for OMP development Market exclusivity for 10 years (reviewed
after 5 years)
Market exclusivity for 7 years (not reviewed)
Protocol assistance and fee reductions 50% tax credit for clinical trials
Protocol assistance and fee reductions
Research grants ear-marked for orphan disease
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products can be placed on the market unless superiority
is demonstrated. In a few cases this has produced con-
fusion and legal challenge regarding the amount of evi-
dence needed to prove superiority [11], but market
exclusivity is still a powerful incentive for OMP devel-
opment. In Europe (not the USA), the period of market
exclusivity may be reduced to 6 years if, after 5 years,
the drug is deemed ‘sufficiently profitable’. The profits
of the first OMPs with European market approval will
be reviewed in 2006 [Replagal and Fabrazyme]. Cer-
tainly, the OMP market can be very profitable. Indeed,
in 2004, a total of nine OMPs each generated sales
revenues in excess of US$1 billion [12]. However, the
definition of ‘sufficiently profitable’ in the context of
European Orphan Drug law is unclear. The EC has com-
missioned a fact-finding study [13] and is currently
defining the procedure which will be used to review an
OMP’s orphan status 5 years after marketing. This deci-
sion may have considerable impact on future OMP
development [14]. Market exclusivity is the main incen-
tive for OMP development in Europe because tax credits
cannot be legislated at the European level (unlike the
USA, where tax credits are a considerable incentive).
Any loss of years with market exclusivity will poten-
tially deter future OMP development.
A drug developed with the benefits of orphan status
may subsequently develop an indication for a common
condition. Bosentan was developed with orphan status
as a therapy for pulmonary hypertension but it might
subsequently have also had a role in the treatment of
heart failure, an area in which large clinical trials were
undertaken [15]. This would have presented the oppor-
tunity of larger profits for the OMP producer or the
possibility of a reduction in drug price for patients with
orphan diseases. In reverse, a drug for a common con-
dition might gain orphan status to treat a rare disease.
An example would be sildenafil, currently licensed for
erectile dysfunction, which has orphan status and recent
 
Table 3
 
Orphan medicinal products with market approval in Europe
 
Date of
designation
as OMP Drug name Orphan disease indication Trade name
Date of
market
authorization
 
12/12/2003 Sildenafil citrate Treament of pulmonary arterial hypertension and chronic
thromboembolic pulmonary hypertension
Revatio 4/11/2005
9/7/2001 Ziconotide (intraspinal use) Treatment of chronic pain requiring intraspinal analgesia Prialt 24/2/2005
29/12/2000 Nitisinone Treatment of tyrosinaemia type I Orfadin 21/2/2005
29/12/2000 Anagrelide hydrochloride Treatment of essential thrombocythaemia Xagrid 16/11/2004
31/7/2001 Zinc acetate dihydrate Treatment of Wilson’s disease Wilzin 18/10/2004
14/2/2001 Ibuprofen Treatment of patent ductus arteriosus Pedea 29/7/2004
12/6/2002 Mitotane Treatment of adrenal cortical carcinoma Lysodren 30/4/2004
18/9/2001 Cladribine (subcutaneous use) Treatment of indolent non-Hodgkin’s lymphoma Litak 14/4/2004
6/3/2002 Porfimer sodium (for use with
photodynamic therapy)
Treatment of high-grade dysplasia in Barrett’s oesphagus PhotoBarr 25/3/2004
20/11/2001 Celecoxib Treatment of familial adenomatous polyposis Onsenal 17/10/2003
29/12/2000 Iloprost Treatment of pulmonary hypertension Ventavis 16/9/2003
29/12/2000 Busulfan (intravenous use) Conditioning treatment prior to haematopoietic 
progenitor cell transplantation
Busilvex 9/7/2003
14/2/2001 Laronidase Treatment of mucopolysaccharoidosis, type I Aldurazyme 10/6/2003
18/10/2000 N-carbamyl-L-glutamic acid Treatment of N-acetylglutamate synthetase (NAGS)
deficiency
Carbaglu 24/1/2003
18/10/2000 Miglustat Treatment of Gaucher disease Zavesca 20/11/2002
14/2/2001 Pegvisamant Treatment of acromegaly Somavert 13/11/2002
14/2/2001 Bosentan Treatment of pulmonary arterial hypertension and chronic
thromboembolic pulmonary hypertension
Tracleer 15/5/2002
18/10/2000 Arsenic trioxide Treatment of acute promyelocytic leukaemia Trisenox 5/3/2002
14/2/2001 Imatinib mesylate Treatment of chronic myeloid leukaemia and treatment of
gastrointestinal stromal tumours
Glivec 27/8/2001
8/8/2000 Alpha-galactosidase A Treatment of Fabry disease Replagal 4/5/2001
8/8/2000 Alpha-galactosidase A Treatment of Fabry disease Fabrazyme 4/5/2001
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market approval for the treatment of pulmonary arterial
hypertension and chronic thromboembolic pulmonary
hypertension. Should a drug which is commonly pre-
scribed be more expensive when it is being used to treat
an orphan disease? In some cases, the cost of OMP
development would be substantially reduced as some
elements of safety would already be established, and
might provide a rationale for expecting a reduced price
compared with existing OMPs without mainstream
indications.
The market exclusivity granted to OMPs is a superior
incentive to patent protection [10]. To receive patent
protection the drug producer needs to demonstrate nov-
elty, whereas for market exclusivity the producer needs
only orphan status. Therefore, drugs that would be inel-
igible for patent protection may be attractive targets for
orphan diseases (e.g. ibuprofen has orphan status for the
prevention of patent ductus arteriosus in premature neo-
nates). Another advantage of orphan status is that market
exclusivity commences with drug approval. In compar-
ison, patents are commonly applied for and awarded
early in product development so that many years of
patent protection can be lost before the drug is available
on the market.
 
Protocol assistance and fee reductions
 
The COMP has highlighted the importance of protocol
assistance in guiding orphan products towards a suc-
cessful application for marketing authorization with
good quality safety and efficacy data. Orphan drugs are
also eligible for reductions in the fees incurred during
development. In Europe this includes fees for preautho-
rization activities, such as protocol assistance, the
application fee for marketing authorization, and postau-
thorization fees. Since 2002, subject to the availability
of funds, 100% fee reduction for protocol assistance and
50% fee reduction for all other fees have been agreed.
Accordingly, €
 
3.7 million (UK £2.5 million) was avail-
able in 2005 for fee exemptions.
 
Tax credits and grants
 
An important difference between the incentives for
OMP development in Europe and the USA is the pres-
ence of tax credits and ear-marked grants in the latter.
The nature of taxation in Europe (being controlled by
individual member states) means that Europe-wide tax
incentives are not possible. Funding set aside specifi-
cally for research in orphan disease is also lacking in
Europe. Tax credits and grants may explain the higher
number of OMPs with market approval in the USA
compared with Europe (Table 2).
 
Marketing approval for orphan medicinal products
 
Before an OMP can be made available for widespread
clinical use it must have marketing approval. Patients
with orphan diseases have a right to be treated with
drugs which are both safe and effective [4]. However,
the evidence base for market approval of OMPs may
be poorer than that for non-orphans, given that the
rare-disease patient population will, by definition, be
small. These limitations may compromise clinical trial
design, although sometimes rare disease populations
will be large enough for double-blind, randomized,
controlled studies. As mentioned earlier, an orphan
disease with a prevalence of five per 10 000 may have
30 000 cases in the UK – a population large enough
for well-designed clinical trials. Nevertheless, for very
rare diseases multiple geographically distinct sites
may be needed and this will increase the cost of the
study considerably.
OMP development was recently assessed by Joppi
 
et al.
 
 [16, 17]. Their study [16] critically appraised the
quality of drug dossiers for OMPs with market approval
in Europe. A common weakness of market applications
for OMPs was small patient numbers in clinical trials.
While this may be understandable for very rare diseases,
it is perhaps not for diseases such as cystic fibrosis (which
has 10 European OMPs, none approved) with a patient
population of approximately 20 000 in Europe. The stud-
ies were also commonly placebo controlled, when it
might have been expected that an existing treatment
should have been the active comparator. The authors also
found that trials were too short in relation to the natural
history of the disease and surrogate end-points were often
used without strong evidence of validity.
The incentives offered to OMPs aim to compensate
for the small disease market. Therefore, orphan status
should not necessarily allow a reduction in the quality
 
Table 4
 
Examples of ultra-orphan medicinal products (uOMPs) 
nearing market approval
 
uOMP name Disease
Stage of
development
 
α
 
1
 
-glucosidase alfa Pompe’s disease Applied for approval
Galsulfase MPS VI Applied for approval
Iduronate-2-sulfatase Hunter’s syndrome Late clinical trials
OGT 923 Sandhoff’s disease Early clinical trials
Miglustat Nieman–Pick
disease
Early clinical trials
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of evidence presented for market approval. Some con-
ditions will be very rare and the evidence base will be
reduced (ultra-orphan conditions) but often patient num-
bers will be sufficient for well-designed clinical studies.
 
The ultra-orphan medicinal products and 
public funding
 
There is no EU definition of ultra-orphan disease but the
UK NICE recently used a prevalence of 
 
<
 
1000 people
in England and Wales to define ultra-orphan status. As
these diseases are very rare, the evidence base for a new
treatment’s efficacy and safety is likely to be small and
the treatment expensive, giving a high and relatively
imprecise incremental cost–effectiveness ratio (ICER).
As an example, Cerezyme (imiglucerase
 
)
 
 is an ultra-
orphan medicinal product (uOMP) for the treatment of
Gaucher disease. The cost of treatment with this drug is
approximately €
 
580 000 (UK £400 000) per adult per
year (personal communication). The high financial cost
of certain OMPs creates a conflict between the rights of
the individual and the health of society as a whole.
Should the priority for a nation’s finite health budget be
the greatest health gain for the greatest number, or is this
less important than the right of every individual to treat-
ment even if that treatment does not offer the largest
health gain for its financial cost? This will remain an
important issue as several drugs of this type are cur-
rently awaiting approval (Table 4).
As already discussed, the EU provides legislation
regarding incentives for OMP/uOMP development.
However, there is no EU legislation to guide the use of
OMP/uOMPs in member states once the products have
market approval. In fact, there are considerable differ-
ences in the availability and price of OMPs when Euro-
pean countries are compared [18]. Different countries
have different bodies that produce recommendations on
the use of treatments. For example, in Scotland, the
Scottish Medicines Consortium (SMC) has reviewed six
OMPs and recommended the use of four, even though
the ICER was one of the guides to acceptance. As more
OMPs and uOMPs gain market approval, a challenge
for agencies such as NICE and SMC is to develop pro-
tocols and criteria so that products can be objectively
evaluated and consistent decisions made.
There are ethical arguments for and against the public
funding of ultra-orphan drug use. A utilitarian viewpoint
(greatest benefit for the greatest number) might favour
a limit on spending as each ultra-orphan disease repre-
sents few individuals so it is not maximizing the benefit
of that spending to society [19]. When the cost effec-
tiveness of health interventions is compared then the
ICER is often expressed as a cost per QALY (see
Table 1). In chronic myeloid leukaemia, imatinib
(Glivec), for instance, has an estimated ICER of
 
€
 
21 000–
 
€
 
75 000 (UK £15 000–£52, 000) per QALY
[20]. This can be compared with general practice-based
advice to stop smoking costing 
 
€
 
390 (UK £270) per
QALY [21]. Thus, when health spending is restricted,
spending on uOMPs does not bring the greatest benefit
to the greatest number of people. In a cash-limited
health system there are likely to be opportunity costs
incurred by funding high cost per QALY treatments,
which serve to restrict the availability of therapies which
offer better value for money and limit the funding avail-
able for health service priorities such as computed tomo-
graphic scanning after stroke, reduction of cancer
treatment waiting times and recruitment of health ser-
vice staff. In fact, the utilitarian could argue that by
funding expensive uOMPs, patients with more common
conditions are being deemed less worthy of treatment
(‘why should a patient with a very rare disease receive
treatment at the expense of 10 with common equally
serious conditions?’) [22]. Many ultra-orphan diseases
produce chronic disability and significantly reduce qual-
ity of life and this is a strong argument to support public
funding for treatments. However, it must not be forgot-
ten that common conditions such as lung cancer and
heart failure can also produce pain and disability, but
their treatments may be more cost effective. The evi-
dence base supporting the clinical efficacy of treatments
for ultra-orphan disease will commonly be based on
trials with only a small number of patients. Therefore,
in addition to incurring a high cost there may be large
uncertainty about the clinical effectiveness.
A widely held and powerful alternative view is that
society should not abandon individuals who are unfor-
tunate enough to develop a serious condition that is rare,
applying the ‘rule of rescue’, a term used to describe the
imperative people feel to rescue identifiable individuals
facing avoidable death [23]. This is enshrined in EU
legislation, which states ‘that patients suffering from a
rare condition should be entitled to the same quality of
treatment as other patients’ [4]. Also, treatments may be
expensive for the individual but, if the disease is very
rare, the impact on a nation’s overall health budget is
going to be small.
The funding of uOMPs has recently been debated by
a Citizens’ Council organized by NICE [24]. This was
a lay group educated for 3 days about the issues sur-
rounding uOMPs and then asked to decide whether
these treatments should be funded by the National
Health Service (NHS). The results reflect the complexity
of the issues. Around half of the 30 members of the
Council thought that, with certain conditions, the NHS
 J. W. Dear et al. 
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should consider paying for high-cost uOMPs. This high
expenditure should be conditional on the degree of dis-
ease severity, the ability of the drug to provide health
gain and whether the disease was life-threatening. How-
ever, seven members thought that the NHS should not
consider paying the premium prices but rather treat
ultra-orphan disease with the same clinical and cost-
effectiveness rules as any other disease. On the other
hand, four members concluded that the NHS should pay
any price required to treat a patient with a very rare
disease, irrespective of disease severity.
Several possible options are available to develop cri-
teria on which funding decisions for uOMPs can be
based [22].
• Individual decisions could be made with modifying
factors such as disease severity, potential of the treat-
ment to reverse the disability rather than slow further
disease progression, or the potential for a uOMP to
bridge to receipt of a definitive treatment such as
transplantation. However, these factors will differ with
each ultra-orphan disease, which makes comparison
across illnesses difficult and subjective.
• The decision to recommend public funding may be
based on the cost per QALY of existing treatments.
• Ultra-orphan diseases could be weighted so that as a
disease becomes less common a higher cost per
QALY is accepted. This QALY weighting has the
advantage that it allows threshold values of cost effec-
tiveness to be created based on disease prevalence.
These thresholds make decisions about funding trans-
parent and can guide price negotiations with pharma-
ceutical companies. However, QALY weighting
would be rejected if a utilitarian viewpoint is applied
– ‘why are rare disease QALYs more valuable, surely
all QALYs are equal’?
• A country’s government may enter a risk-sharing
agreement such that if agreed health gains are not
achieved the cost of the treatment will be paid by the
treatment producer. This has been used for the treat-
ment of multiple sclerosis [25], but whether it would
be applicable to, or realistic for, all uOMPs is unclear.
• Ultra-orphan diseases could have their funding ‘ring-
fenced’ into a dedicated health service fund, or fund-
ing could be provided from charities or research coun-
cils with the treatments being delivered through
clinical trials. In England some uOMPs are commis-
sioned ‘centrally’ by the National Specialist Commis-
sioning Advisory Group [26]. An example would be
enzyme replacement therapy for lysosomal storage
diseases, which cost 
 
€
 
75 million (UK £52 million)
this financial year (personal communication). How-
ever, this is a cost levied from primary care trusts and
has been criticized from a utilitarian viewpoint as an
unacceptable opportunity cost that is centrally man-
dated from the budgets of local services [27].
Patients with ultra-orphan diseases receiving licensed
uOMPs should be carefully monitored and the treatment
should be stopped if not producing benefit. The ‘stop-
ping rules’ for OMPs need to be clearly defined to
prevent excessive expenditure on cost-ineffective treat-
ments. Difficulties may arise if the treatment is deemed
cost ineffective but the patient is already established on
treatment with clinical benefit, e.g. after the conclusion
of a clinical trial. In the future it may be necessary to
specify in clinical trial protocols a risk-sharing policy
such that the health service will pay for patients to
continue therapy only under prespecified conditions.
 
Conclusion
 
The management of rare disease is a challenging prob-
lem for all countries. Legislation has defined rare or
orphan disease by arbitrary disease prevalence, which
grants incentives to OMP producers. There are over
5000 rare diseases and in Europe so far 21 OMPs have
been granted marketing approval. It is hoped that for
patients suffering from previously neglected orphan dis-
eases many more OMPs will be approved. However, in
addition to increasing the number of OMPs reaching the
market place, society needs to debate and better under-
stand the funding issues so that reasonable criteria can
be established by which cost effectiveness can be con-
 
sistently and transparently determined.
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